Updated: Two years after launch, Third Rock-backed neuro startup Faze Medicines is closing its doors — report

Lei Lei Wu

News Reporter

In 2020, the biotech market was propelled upward by Covid-19, as money flowed quickly into the industry. In December of that year, Faze Medicines launched …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Two years after launch, Third Rock-backed neuro startup Faze Medicines is closing its doors — report

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Merck KGaA closes in on SpringWorks deal at $3.5B price point

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Up­dat­ed: Two years af­ter launch, Third Rock-backed neu­ro start­up Faze Med­i­cines is clos­ing its doors — re­port

News Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Updated: Two years after launch, Third Rock-backed neuro startup Faze Medicines is closing its doors — report